Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study

Author： Muller Laurent   Jaber Samir   Raillard Alice   Lefrant Jean  

Publisher： Springer Publishing Company

ISSN： 0342-4642

Source： Intensive Care Medicine, Vol.34, Iss.5, 2008-05, pp. : 977-979

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Recombinant Factor VII (Activated) for Haemorrhagic Complications of Severe Sepsis Treated with Recombinant Protein C (Activated)

By  

Acta Haematologica, Vol. 116, Iss. 2, 2006-08 ,pp. : 126-130

Karger

Access to resources Recommend Favorite

Recombinant human activated protein C in sepsis: previous concerns and current usage

By Haley Michael   Cui Xizhong   Minneci Peter C   Deans Katherine J   Natanson Charles   Eichacker Peter Q  

Therapy, Vol. 1, Iss. 1, 2004-09 ,pp. : 123-129

Future Medicine

Access to resources Recommend Favorite

Risk factors for 30‐day readmission among patients with culture‐positive severe sepsis and septic shock: A retrospective cohort study

By  

JOURNAL OF HOSPITAL MEDICINE, Vol. 1553-5592, Iss. 10, 2015-10 ,pp. : 678-685

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk factors for 30‐day readmission among patients with culture‐positive severe sepsis and septic shock: A retrospective cohort study

By  

JOURNAL OF HOSPITAL MEDICINE, Vol. 10, Iss. 10, 2015-10 ,pp. : 678-685

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study

By Kanji Salmaan   Perreault Marc   Chant Clarence   Williamson David   Burry Lisa  

Intensive Care Medicine, Vol. 33, Iss. 3, 2007-03 ,pp. : 517-523

Springer Publishing Company

Access to resources Recommend Favorite